Cancer treatment using viruses, fluoropyrimidines and camptothecins
Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.
1. A method of treating a mammalian subject having a neoplasm, comprising administering to the subject a replication competent Newcastle Disease virus, a fluoropyrimidine compound, and a camptothecin compound in one or more cycles in a combined amount effective to treat the subject.
2. The method of claim 1 , wherein the virus is a mesogenic strain of Newcastle Disease virus.
3. The method of claim 1 , wherein the virus is administered intravenously.
4. The method of claim 1 wherein the fluoropyrimidine compound is 5-fluorouracil.
5. The method as in claim 4 further comprising administering to the subject leucovonn.
6. The method as in claim 4 wherein the 5-fluorouracil is administered by continuous infusion over a period of at least 22 hours per dose.
7. The method of claim 1 wherein the camptothecin compound is selected from the group consisting of topotecan, 9-aminocamptothecin, exatecan, karenitecin, rubitecan, lurtotecan, and a homocamptothecin.
8. The method of claim 1 , wherein the camptothecin compound is irinotecan.
9. The method of claim 1 , wherein the virus is a mesogenic strain of Newcastle Disease Virus, the fluoropyrimidine compound is 5-fluorouracil, and the camptothecin compound is irinotecan.
10. The method of claim 1 , wherein the virus, the fluoropyrimidine compound, and the camptothecin compound are administered in two or more cycles.
11. The method of claim 1 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one month before administration of the virus.
12. The method of claim 11 , wherein camptothecin compound is administered to the subject from twenty-four hours to one week before administration of the virus.
13. The method of claim 1 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one month after administration of the virus.
14. The method of claim 13 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one week after administration of the virus.